Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Nov 14:8:267.
doi: 10.1186/1748-717X-8-267.

Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials

Wilfried Budach  1 , Kai Kammers, Edwin Boelke, Christiane Matuschek
Affiliations
Meta-Analysis

Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials

Wilfried Budach et al. Radiat Oncol. .

Abstract

Background: Radiotherapy (RT) improves overall survival (OS) of breast cancer patients after breast conserving surgery and after mastectomy in patients with involved lymph nodes (LN). The contribution of RT to the regional LN to this survival benefit was poorly understood. Recently, the results of three large randomized trials addressing this question have become available.

Material and methods: The published abstracts (full publication pending) of the MA.20 (n=1832) and the EORTC 22922-10925 (EORTC) (n=4004) trial and the full publication of the French trial (n=1334) were basis of the meta-analysis. Main eligibility criteria were positive axillary LN (all trials), LN negative disease with high risk for recurrence (MA.20), and medial/central tumor location (French, EORTC). The MA.20 and the EORTC trial tested the effect of additional regional RT to the internal mammary (IM) LN and medial supraclavicular (MS) LN, whereas in the French trial all patients received RT to the MS-LN and solely RT to the IM-LN was randomized. Primary endpoint was OS. Secondary endpoints were disease-free survival (DFS) and distant metastasis free survival (DMFS).

Results: Regional RT of the MS-LN and the IM-LN (MA.20 and EORTC) resulted in a significant improvement of OS (Hazard Ratio (HR) 0.85 (95% CL 0.75 - 0.96)). Adding the results of the French trial and using the random effects model to respect the different design of the French trial, the effect on OS of regional radiotherapy was still significant (HR 0.88 (95% CL 0.80 - 0.97)). The absolute benefits in OS were 1.6% in the MA.20 trial at 5 years, 1.6% in the EORTC trial at 10 years, and 3.3% in the French trial at 10 years (not significant in single trials). Regional radiotherapy of the MS-LN and the IM-LN (MA.20 and EORTC) was associated with a significant improvement of DFS (HR 0.85 (95% CL 0.77 - 0.94)) and DMFS (HR 0.82 (95% CL 0.73 - 0.92)). The effect sizes were not significantly different between trials for any end point.

Conclusion: Additional regional radiotherapy to the internal mammary and medial supraclavicular lymph nodes statistically significantly improves DFS, DMFS, and overall survival in stage I-III breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial designs. Random = randomization. RT = radiotherapy. MS-LN-RT = radiotherapy of medial supraclavicular lymph nodes. MS-IM-RT = radiotherapy of medial supraclavicular and internal mammary lymph nodes.
Figure 2
Figure 2
Overall survival. The area of the symbols reflect the number of patients, MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation, MS = medial supraclavicular lymph node irradiation.
Figure 3
Figure 3
Disease free survival. The area of the symbols reflect the number of patients. MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.
Figure 4
Figure 4
Distant metastasis free survival. The area of the symbols reflect the number of patients, MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.
See this image and copyright information in PMC

References

    1. Darby S, McGale P, Correa C. et al.Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. - PMC - PubMed
    1. Sedlmayer F, Sautter-Bihl ML, Budach W. et al.DEGRO practical guidelines:radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013;189:825–833. doi: 10.1007/s00066-013-0437-8. - DOI - PMC - PubMed
    1. Clarke M, Collins R, Darby S. et al.Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106. - PubMed
    1. Glechner A, Wockel A, Gartlehner G. et al.Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49:812–825. doi: 10.1016/j.ejca.2012.09.010. - DOI - PubMed
    1. Engel J, Emeny RT, Holzel D. Positive lymph nodes do not metastasize. Cancer Metastasis Rev. 2012;31:235–246. doi: 10.1007/s10555-011-9343-7. - DOI - PubMed

Publication types